Clinical experiences with magnetic drug targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors

Cancer Research

Volumn 56, Issue 20, 1996, Pages 4686-4693

  Lübbe, Andreas Stephan ^a,b   Bergemann, Christian ^a   Riess, Hanno ^a   Schriever, Folke ^a   Reichardt, Peter ^a   Possinger, Kurt ^a   Matthias, Michael ^a   Dörken, Bernd ^a   Herrmann, Friedhelm ^a   Gürtler, Renate ^a   Hohenberger, Peter ^a   Haas, Norbert ^a   Sohr, Reinhard ^a   Sander, Bernhard ^a   Lemke, Arne Jürgen ^a   Ohlendorf, Dieter ^a   Huhnt, Winfried ^a   Huhn, Dieter ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Cecilien Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; FEMALE; HISTIOCYTOMA; HUMAN; MAGNETIC FIELD; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DRUG DELIVERY SYSTEMS; EPIRUBICIN; FEMALE; FERRITINS; HUMANS; IRON; MAGNETICS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0038833905     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Gupta, P. K , and Hung, C. T Magnetically controlled targeted chemotherapy. In: N. Willmott and J. Daly (eds.), Microspheres and Regional Cancer Therapy, pp. 1-59. Boca Raton, FL. CRC Press, Inc , 1993
2. Gupta, P. K. Drug targeting in chemotherapy. a clinical perspective J. Pharm. Sci , 79: 949-962, 1990.
3. Juliano, R. L. (ed), Targeted Drug Delivery. Berlin, Springer-Verlag, 1991.
4. Leyland-Jones, B Targeted drug delivery. Semin Oncol., 20: 12-17, 1993.
5. Florence, A. T., and Halbert, G. W. Drug delivery and targeting Phys Technol , 16: 164-192, 1985.
6. Meijer, D. K. F., Jansen, R. W., and Molema, G Drug targeting systems for antiviral agents: options and limitations. Antiviral Res., 18: 215-258, 1992
7. Gottstein, C., Winkler, U , Bohlen, H , Diehl, V , and Engert, A. Immunotoxins: is there a clinical value? Ann. Oncol., 5: 97-103, 1994.
8. Sezaki, H., and Hashida, M. Macromolecule drug conjugates in targeted cancer chemotherapy Crit Rev. Ther. Drug Carrier Syst., 1: 1-38, 1984.
9. Gregoriadis, G., and Florence, A. T. Liposomes in drug delivery. Clinical, diagnostic, and ophthalmic potential. Drugs, 45: 15-28, 1993.
10. Illum, L., and Davis, S. S (eds.), Polymers in Controlled Drug Delivery. Bristol, United Kingdom. John Wright and Sons Ltd., 1987
11. Widder, K. J., Senyei, A. E., and Ranney, D F Magnetically responsive microspheres and other carriers for the biological targeting of antitumor agents. In: S. Gavattini, A. Goldin, F Howkin, I. J. Kopin, and R. J Schnitzer (eds.), Advances in Pharmacology and Chemotherapy, pp. 213-239. New York: Academic Press, 1979.
12. Widder, K J., Senyei, A. E , and Scarpelli, D. G Magnetic microspheres a model system for site specific drug delivery in vivo. Proc. Soc. Exp. Biol. Med., 58. 141-146, 1978.
13. Widder, K J , Morris, R. M , Poore, G A., Howards, D P., and Senyei, A. E. Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in Yoshida sarcoma-bearing rats. Eur. J. Cancer Clin. Oncol , 19: 135-139, 1983.
14. Gupta, P K., and Hung, C. T. Targeted delivery of low dose doxorubicin hydrochloride administered via albumin microspheres in rats J. Microencapsulation, 7: 85-92, 1990.
15. Lübbe, A S , Bergemann, C., Huhnt, W , Fricke, T., Riess, H., Reichardt, P , and Huhn, D. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res , 56: 4694-4701, 1996.
16. Scheulen, M E Klinische Pharmakologie der wochentlich fraktionierten Behandlung mit Epirubicin In M E Scheulen, and N. Niederle (eds.). Wochentlich fraktioniertes Epirubicin. Klinische Pharmakologie und Indikationen, pp 3-25. Munich Zuckerschwerdt, 1989
17. Launchbury, A. P , and Habboubi, N Epirubicin and doxorubicin a comparison of their characteristics, therapeutic activity and toxicity Cancer Treat. Rev , 19: 197-228, 1993.
18. Bonadonna, G , Gianni, L , Santoro, A., Bonfante, V , Bidoli, P , Casali, P., Demichelis, R , and Valagussa, P. Drugs ten years later, epirubicin Ann Oncol., 4 359-369, 1993
19. Camaggi, C. M., Strocchi, E , Carisi, P., Martoni, A., Melotti, B., and Pannuti, F. Epirubicin metabolism and pharmacokinetics after conventional and high-dose intravenous administration, a cross-over study Cancer Chemother. Pharmacol , 32 301-309, 1993
20. Mross, K , Maessen, P , van der Vijgh, W. J. F , Gall, H , Boven, E., and Pinedo, H. M. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans J Clin. Oncol , 6 517-526, 1988.
21. Weisleder, R , Stark, D. D , Engelstad, B L , Bacon, B R , Compton, C C., White, D. L., Jacobs, P , and Lewis, J Superparamagnetic iron oxide pharmacokinetics and toxicity. AJR Am J Roentgenol., 152: 167-173, 1989
22. Ferruci, J. T., and Stark, D D. Iron-enhanced MR imaging of the liver and spleen: review of the first 5 years AJR Am. J. Roentgenol. 155, 943-950
23. Van Hecke, P., Marchal, G., Decrop, E., and Baert, A L Experimental study of the pharmacokinetics and dose response of ferrite particles used as contrast agent in MRI of the normal liver of the rabbit Invest. Radiol , 24 397-399, 1989.